Olema Pharmaceuticals (OLMA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
The annual meeting will be held virtually on June 17, 2026, with voting on director elections, executive compensation, and auditor ratification.
Stockholders of record as of April 23, 2026, are eligible to vote, with 87,346,132 shares outstanding.
Proxy materials are available online, and voting can be done electronically, by phone, or by mail.
Voting matters and shareholder proposals
Four Class III directors are nominated for election to serve until 2029.
Advisory vote on executive compensation (say-on-pay) is scheduled.
Ratification of Ernst & Young LLP as independent auditor for 2026 is up for vote.
Shareholder proposals for the 2027 meeting must be submitted by January 1, 2027.
Board of directors and corporate governance
The board consists of eleven directors, with a majority classified as independent under Nasdaq standards.
Board leadership is separated between the Chairperson and CEO.
Committees include Audit, Compensation, Nominating and Corporate Governance, and Science and Technology.
Directors are selected based on experience, diversity, and independence.
Latest events from Olema Pharmaceuticals
- Net loss rose 44% to $63.2M in Q2 2026 as Phase 3 trial enrollment completed and cash reached $461M.OLMA
Q2 2026 - Pivotal trials and new combinations position the pipeline for major advances in breast cancer care.OLMA
Jefferies London Healthcare Conference 2025 - Phase III breast cancer data expected in fall; KAT6 combos and strong cash position support growth.OLMA
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Promising clinical progress and strategic trial updates position the pipeline for significant impact.OLMA
Jefferies Global Healthcare Conference 2026 - OP-3136 demonstrates early efficacy and safety, with pivotal trial readouts expected this fall.OLMA
7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Signed 7-year triple net lease and advanced clinical pipeline; Q1 net loss $53.1M, cash $505.3M.OLMA
Q1 2026 - Virtual meeting to elect directors, approve pay, and ratify auditor, with board support.OLMA
Proxy filing - Advanced late-stage trials and strengthened cash position with $218.5M raised in 2025.OLMA
Q4 2025 - Pivotal breast cancer trials advance with promising efficacy and key data readouts expected soon.OLMA
TD Cowen 46th Annual Health Care Conference